Industrial Policy & Trade Monitor· 2665 actions· ✨ 90 recent

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

The Office of the United States Trade Representative released the 2026 Special 301 Report on 30 April 2026, designating Vietnam as a Priority Foreign Country (PFC) — the most severe category under Section 182 of the Trade Act of 1974 (19 U.S.C. § 2242). This is the first PFC designation since Ukraine held the status from 2013 through 2015, a gap of approximately 11 years. The PFC designation triggers a statutory 30-day window (expiring ~30 May 2026) within which USTR must decide whether to initiate a Section 301 investigation under 19 U.S.C. § 2412(b)(2)(A), which could lead to tariffs, withdrawal of trade benefits, or other Section 301 enforcement remedies against Vietnam. Separately, the EU was added to the Watch List for the first time, citing AI training-data, geographical-indications, and customs-enforcement concerns.

On 26 April 2026, the UAE Cabinet, chaired by Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum, approved a four-part industrial-resilience package: (i) a National Industrial Resilience Fund with AED 1 billion (~USD 272m) capital managed by Emirates Development Bank over five years covering food industries, manufacturing, primary metals, mechanical/electrical/chemical industries, pharmaceuticals and medical supplies, advanced technology, and construction — designed to localise over 5,000 critical products and link confirmed procurement demand with targeted financing for local manufacturers; (ii) structural overhaul of the National In-Country Value (ICV) Programme, transitioning it from incentive-based to MANDATORY across federal entities and companies in which the government holds 25% or more; (iii) a National Product Retail Presence Policy strengthening visibility of UAE-manufactured goods in retail and digital channels (Phase 1: bottled water, dairy, eggs, poultry, bread, flour, vegetable oils, seasonal vegetables); and (iv) a National Industrial Data Committee chaired by Hasan Jassim Al Nowais (Undersecretary, MoIAT), with AI-driven forecasting and risk management integrated into industrial-resilience monitoring.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

Premier Li Qiang signed State Council Order No. 834 on 31 March 2026 promulgating the "Provisions on Industrial Chain and Supply Chain Security" (18 articles), adopted at the State Council executive meeting on 13 March 2026 and effective on the date of publication. The Provisions are the first dedicated PRC administrative regulation on industrial- and supply-chain security and consolidate authorities drawn from the National Security Law, Foreign Relations Law, Anti-Foreign Sanctions Law, and Foreign Trade Law into a horizontal defensive framework. They establish a cross-agency coordination mechanism spanning roughly 15 central departments (industrial, security, cyberspace, customs and financial regulators) plus provincial governments; create a security-investigation system; and vest broad countermeasure authority over both foreign states (Article 14 — import/export prohibitions and special levies) and foreign organisations and individuals (Article 15 — import/export bans, China-investment bars, transaction prohibitions, entry bars and revocation of work or residence permits, with extension to effectively-controlled subsidiaries). The Provisions also impose compliance, information-sharing, strategic-reserve and emergency-response obligations on PRC organisations and individuals, and authorise requisition, mandated production and directed transportation in the event of supply-chain disruption.

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX) adopted Resolução GECEX nº 855 on 13 February 2026, imposing a five-year definitive antidumping duty on hypodermic needles (agulhas hipodérmicas) originating from China, classified under NCM tariff code 9018.32.19 (other tubular metal needles). The duty is collected as a specific tariff fixed in US dollars per thousand units, with rates ranging from USD 0.23 to USD 25.57/thousand units depending on the Chinese producer/exporter. The measure was published in the Diário Oficial da União (DOU Edição 32) on 18 February 2026, enters into force from publication, and marks the first medical-device trade-remedy action on the IPTM register. Scope exclusions cover insulin needles, biopsy needles, animal insemination needles, anesthesia needles, bulk non-sterile needles, and non-hypodermic needles.

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

Brazil's federal innovation-financing agency FINEP (Financiadora de Estudos e Projetos), under the MCTI/FNDCT umbrella, published a BRL 300 million (~USD 51.7 million) public call — "Finep Mais Inovação Brasil – Rodada 2 – Saúde" — offering non-repayable economic-subsidy grants for private-sector R&D of innovative products or processes for Brazil's health-industrial complex (pharmaceuticals, health-sector chemical inputs). A minimum BRL 90 million is reserved for projects based in the North, Northeast or Center-West regions. Proposal submission opened 2026-02-06 and runs through 2026-09-18.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

The Commonwealth of Pennsylvania, via Governor Josh Shapiro's office and the Department of Community & Economic Development, assembled a $100 million public incentive package — up to $50 million via the PA Edge Tax Credit Program, a $25 million PA SITES (Strategic Investments to Enhance Sites) grant, a $25 million Pennsylvania First grant, and up to $5 million via the Redevelopment Assistance Capital Program (RACP) for workforce development — to secure a $3.5 billion private investment from Eli Lilly and Company, the company's first manufacturing facility in Pennsylvania. The 925,000-square-foot facility will be built at the Fogelsville Corporate Center in Upper Macungie Township, Lehigh County, to produce next-generation weight-loss medicines, creating at least 850 new jobs over five years. It is the largest life-sciences investment in Pennsylvania history.

Malaysia replaced its four-decade-old Promotion of Investments Act (PIA) 1986 manufacturing-incentive regime with the New Incentive Framework (NIF), effective 1 March 2026. Applications under PIA 1986 closed at 15:00 MYT on 28 February 2026; post-March applications are evaluated under the outcome-based National Investment Aspirations (NIA) Scorecard across six economic-outcome pillars. Companies choose between two mutually exclusive incentive options — a special corporate tax rate or an investment tax allowance — aligned with the Global Minimum Tax environment. A services-sector phase is scheduled for Q2 2026.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 848, de 29 de janeiro de 2026, amending Annexes IV (supply-shortage tariff reductions), V (Letec exceptions list) and VI (LEBIT/BK — IT/telecom and capital-goods exceptions list) of the base tariff-nomenclature resolution (Gecex nº 272/2021). The measure grants a new 0% duty-free tariff-rate quota of 2,500 tonnes/year for poly(oxyethylene) methallyl ether (HPEG, NCM 3907.29.92) through 26 November 2026; adds 0% duty treatment for an esketamine hydrochloride nasal-spray medicine (NCM 3004.90.39) and several pharmaceutical active ingredients including amprenavir and efavirenz (NCM 3004.90.78); and adds cellular base-station antennas (NCM 8517.71.20, 25,000-unit quota through 19 August 2026), diesel-electric locomotives (NCM 8602.10.00, through 25 February 2027) and panoramic maxillary X-ray equipment (NCM 9022.13.11, at a 12.6% rate) to the LEBIT/BK exceptions list. Most changes take effect 1 February 2026 (some 2 February 2026); Article 7 directs SECEX to publish complementary quota-allocation criteria.

The European Investment Bank signed a EUR 400 million, seven-year loan agreement with Swedish hygiene and health group Essity on 29 January 2026 (EIB project ref. 20210374, "Essity Health and Hygiene Products RDI") to finance research, development and innovation expenditure at Essity's R&D centres in Sweden, Germany and France over 2025-2028. The financing targets product and process development across Personal Care, Professional Hygiene and medical wound care, with emphasis on replacing fossil-based plastics with bio-based materials, cutting greenhouse-gas emissions and expanding digital manufacturing solutions; roughly 30% of the RDI spend is earmarked for feminine-care and incontinence-product research. Global Trade Alert separately logs the transaction as a "red"-flagged state-linked lending intervention (state act 96020 / intervention 151945).

India's DGFT issued Notification No. 56/2025-26 on 29 January 2026, amending the import policy under Chapter 29 of ITC (HS) 2022 to impose minimum import prices (MIPs) on three antibiotic Active Pharmaceutical Ingredients (APIs): Penicillin G-potassium (₹2,216/kg CIF), Amoxycillin trihydrate (₹2,733/kg CIF), and 6-Aminopenicillanic Acid/6-APA (₹3,405/kg CIF). Imports below these price floors are reclassified from "Free" to "Restricted" status, requiring a DGFT import authorisation before Customs clearance. The measure takes immediate effect and is valid for approximately ten months (until 30 November 2026), with an implied renewal pathway. It is explicitly aimed at preventing very-low-priced imports and supporting domestic manufacturers built under the PLI Bulk Drugs scheme, targeting China's dominant position in global antibiotic-fermentation supply.

The UK Department of Health and Social Care added Co-codamol (30mg/500mg, all formulations) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 28 January 2026. DHSC had issued a medicine supply warning for co-codamol 30mg/500mg on 12 January 2026, projecting limited supply into at least early June 2026. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.

China's Ministry of Finance, NDRC, Ministry of Industry and Information Technology, People's Bank of China and National Financial Regulatory Administration jointly issued Cai Jin [2026] No. 4 on 2026-01-19, establishing a central-fiscal loan interest-subsidy scheme for micro, small and medium-sized enterprises (MSMEs) operating in 14 designated industrial-chain and emerging-industry sectors. Eligible loans originated from 2026-01-01 receive a 1.5-percentage-point annual interest subsidy for up to two years, capped at RMB 50 million in principal per enterprise (maximum subsidy RMB 1.5 million per enterprise). The policy is tentatively set to run one year with a possible extension.

On 15 January 2026, Brazil's Gecex executive committee (Câmara de Comércio Exterior) published Resolução nº 845, amending Annex IX of the base tariff-nomenclature resolution (Gecex nº 272/2021) to temporarily raise import duties above the Mercosur Common External Tariff on eight NCM product lines. Affected products include sodium pyrophosphate and ammonium carbonate (17.5%), propylene glycol, expandable polystyrene and polymethyl methacrylate (20%), sorbitol (20%, with a 12.6% carve-out for a specific food/pharma-grade aqueous solution), and wood screws (25%). The increases took effect 19 January 2026 and expire 18 January 2027, a one-year window functioning as a safeguard-style protection for domestic chemical, plastics and fastener producers.

The UK Department of Health and Social Care added Aspirin (all strengths and forms) and Ifosfamide (1g/2g powder for solution for injection vials, a chemotherapy agent) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 January 2026. Pharmacy trade press reported the addition followed manufacturing delays and raw- ingredient shortages that had left UK pharmacies short of aspirin stock. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

On 16 January 2026 the Saudi Council of Ministers, via Cabinet Decision No. 468/1447 (issued 30 December 2025 / 9 Rajab 1447H), published in the Umm Al-Qura Official Gazette four sets of implementing regulations governing the King Abdullah Economic City (KAEC), Ras Al-Khair, Jazan, and Cloud Computing & IT Special Economic Zones. The regulations entered into force on 16 April 2026 (90 days after gazette publication) and operationalise the SEZ framework first launched by ECZA in April 2023. Each zone has its own standalone framework but they share a common headline tax package: 5% corporate income tax for up to 20 years, zero VAT on intra-SEZ and SEZ-import flows, customs-duty suspension on qualifying imports, withholding-tax exemption on dividends and approved cross-border payments, and exemption from key provisions of the Saudi Companies Law, Commercial Register Law, and Trade Names Law. KAEC focuses on advanced manufacturing, automotive, consumer goods, ICT and pharmaceuticals; Ras Al-Khair targets shipbuilding, offshore rigs and MRO; Jazan covers food processing, metals conversion and logistics for Africa-bound trade; the Cloud Computing SEZ is a virtual zone (data centres can sit anywhere in KSA, headquarters must be in Riyadh) for cloud and AI-compute workloads. The package is the operational implementation layer for the 2024 Investment Law and a core Vision 2030 FDI-attraction instrument.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.

At its 30 December 2025 regular session, Iraq's Council of Ministers, chaired by Prime Minister Mohammed Shia' Al-Sudani, approved two additional customs duties on imports from all countries of origin: a 40% additional duty on medical and industrial oxygen (gaseous and liquid forms), in effect for four years, and a 30% additional duty on imported yogurt (laban rayeb) and liquid milk. Both measures were framed as protecting domestic pharmaceutical/ industrial-gas production and local dairy manufacturing respectively, and take effect 120 days after issuance (29 April 2026) to give importers an adjustment window. Global Trade Alert logs the dairy duty as principally affecting Germany, Saudi Arabia and Türkiye as leading supplier origins, though the measure itself is non-discriminatory (applies to all origins).

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).

On 19 December 2025 the Swiss Federal Assembly adopted in final vote the Federal Act on the Screening of Foreign Investments (Bundesgesetz über die Prüfung ausländischer Investitionen, Investitionsprüfgesetz / IPG; popularly the "Lex China", parliamentary business 22.035). The Act introduces Switzerland's first general ex-ante FDI-screening regime: acquisitions of control over Swiss companies active in security-critical sectors by foreign state-controlled investors require prior approval by SECO, with escalation to the Federal Council. The optional- referendum window runs until 17 April 2026; entry into force is not expected before 2027 once implementing ordinances are adopted. Critical sectors named in the Act include military and dual-use goods, electricity grids and generation, water supply, pharma and health, telecommunications, transport infrastructure and financial-market infrastructure.

India's DGFT issued Notification No. 50/2025-26 on 18 December 2025 (Gazette of India, Extraordinary, Part II, Section 3(ii)), inserting a new Policy Condition No. 08 under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy). Imports of diluted Potassium Clavulanate below a CIF value of USD 77/kg, Potassium Clavulanate (KGA) below USD 180/kg, and specified clavulanic-acid-manufacture intermediates below USD 92/kg are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 November 2026. It is aimed at countering low-priced Chinese potassium-clavulanate exports and protecting Indian bulk-drug fermentation capacity (Aurobindo Pharma and other domestic API makers) amid a global potassium-clavulanate supply glut.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

The European Commission approved German State aid of €47 million to Vetter Pharma, a family-owned contract development and manufacturing organisation (CDMO), to support a new aseptic fill-finish plant for injectable pharmaceuticals in Saarlouis, Saarland. The grant is part of a larger ~€480 million first construction phase of the site, which the Commission cleared under EU State aid rules citing job creation (up to 2,000 positions long-term), regional development in Saarland, and consistency with the EU Pharmaceutical Strategy for Europe's goal of securing affordable-medicines manufacturing capacity in the bloc.

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX, under the Ministry of Development, Industry, Trade and Services) approved Resolução Gecex nº 823, at its 231st ordinary meeting (27 November 2025), rebalancing the country's ex-tarifário capital-goods duty-relief regime. Article 1 excludes ex-tarifário duty exemptions from Annex I of Resolução Gecex nº 322/2022 — reverting those products to the standard MFN import tariff. Article 2 grants new duty exemptions by adding items to the Annex Único of Resolução Gecex nº 780/2025. Article 3 amends the technical descriptions of six existing ex-tarifário line items (e.g. automatic pallet-strapping and film-wrapping machines, high-speed horizontal machining centres, injection moulding machines, genset generators) and Article 4 amends five more (including pharmaceutical carpule-filling systems and rotary offset printers). Global Trade Alert's analysis of the resolution counts 2,414 capital-goods products across 317 six-digit NCM headings as affected by the net exclusion/inclusion changes. The resolution took effect on DOU publication (5 December 2025) and was followed same-day by a minor rectification reorganising a handful of entries between Articles 3 and 4 without changing their technical specifications.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 821, de 1º de dezembro de 2025, amending Annex V (Letec — List of Exceptions to the Common External Tariff) and Annex X (List of Temporary Exceptions for Automotive Products under ACE 14) of the base tariff-nomenclature Resolução Gecex nº 272/2021. The resolution took effect on the date of its publication in the Diário Oficial da União. Global Trade Alert tracks the measure as four discrete tariff-line interventions bundled under one state act: (1) an import-tariff increase on butyl and sodium-polyacrylate chemical inputs, effective 5 December 2025; (2) a reduction of the import tariff to zero for a pharmaceutical product under NCM 3004.90.79, effective 5 December 2025; (3) a new import tariff-rate quota for a chemical/pigment product under NCM heading 3306.11, effective 5 December 2025; and (4) an import-tariff increase on 16 medical-device products under NCM 9018.90.99, effective 2 December 2025. Two of the four sub-measures are duty increases (harmful to importers) and two are duty reductions/new liberalising quotas — consistent with Gecex's routine periodic tariff-schedule maintenance cycle rather than a targeted trade-remedy or industrial-policy action.

The UK Department of Health and Social Care, delivered via Innovate UK, awarded more than GBP 54 million in government funding across eight R&D projects on 18 November 2025 through the Sustainable Medicines Manufacturing Innovation Programme, matched by more than GBP 20 million from industry (combined GBP 74m+). The programme is funded through the GBP 400 million VPAG Investment Programme, agreed under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and supports the manufacturing pillar of the UK's Modern Industrial Strategy Life Sciences Sector Plan. Funded projects include anaesthetic gas recovery/recycling (targeting ~GBP 5m annual NHS savings), converting spent nuclear fuel into radionuclide cancer therapies, CAR-T cell manufacturing scale-up (Royal Free Hospital), engineered bacteriophages for antibiotic resistance, and an AstraZeneca-led "Sustainable Future Factory" AI/robotics initiative.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

On 12 November 2025 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2025〕12号, "Several Measures of Beijing Dongcheng District on Promoting Science and Technology Innovation Development," effective 12 December 2025 through 31 December 2028. The package tiers cash grants by milestone: up to RMB 100,000 for first-time high-tech-enterprise certification, RMB 1 million for first-to-market new technology/products, RMB 10 million for incubator and specialised industrial-park upgrades, and up to RMB 30 million for "chain-leader" enterprises or innovation-driving market entities judged to have significant regional radiating/spillover effect. Eligible sectors span new-generation information technology, cultural technology, pharmaceuticals and health, intelligent manufacturing, new materials, and green energy/environmental protection.

On 10 November 2025, China's Ministry of Commerce and four other departments issued Announcement No. 73 of 2025, adjusting the "Catalogue of Precursor Chemicals for Export to Specific Countries (Regions)" and adding the United States, Canada and Mexico to the "Specific Countries (Regions) Directory" under the Interim Provisions on the Management of Exports of Precursor Chemicals to Specific Countries (Regions). Exporters must now apply for a license before shipping 13 newly listed categories of precursor chemicals (used in illicit fentanyl and other synthetic-drug manufacture) to these three countries; exports of the same chemicals to other destinations remain unrestricted. The measure took effect the same day it was announced.

Bangladesh's Council of Advisers, chaired by Chief Adviser Prof. Muhammad Yunus, approved the National Logistics Policy 2025 on 6 November 2025 at its 47th meeting, replacing the annulled 2024 Awami League-era logistics policy. The framework spans 11 chapters and establishes a technology-driven, integrated, sustainable logistics ecosystem aimed at positioning Bangladesh as a leading regional trade and logistics hub by 2050. Two-tier governance architecture: a National Logistics Council (led by the Chief Adviser) for top-level coordination, and a National Logistics Development and Coordination Committee (led by the Chief Adviser's Principal Secretary) for implementation oversight across multimodal hubs, economic zones, international corridors, airports, river ports, sea ports, and land ports.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

Russia's federal Industry Development Fund (FRP) disclosed a RUB 950 million (approx. USD 12 million) concessional loan under its "Development Projects" programme to biopharmaceutical company Nanolek LLC, financing purchase of high-tech equipment for Russia's first domestic human papillomavirus (HPV) vaccine production line. The facility, part of a RUB 7.5 billion total investment in the Orichevsky District of Kirov Region, opened 25-29 October 2025 and produces the "Tsegardeks" vaccine at an initial capacity of over 600,000 doses per year, rising to 3-3.5 million doses annually by 2027 with a planned second production line.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

The UK Office for Life Sciences (OLS) launched the Life Sciences Large Investment Portfolio (LSLIP), a subsidy scheme worth up to GBP 570 million running from implementation in November 2025 to March 2030. The scheme provides direct grants, capped at GBP 130 million per award, to UK-registered private-sector companies committing to invest GBP 250 million or more over three years in domestic manufacturing or commercial R&D across three subsectors: human medicines (APIs and finished products), medical diagnostics, and MedTech. The scheme was referred to the CMA's Subsidy Advice Unit on 21 August 2025, which published its advisory report on 2 October 2025 ahead of the scheme's launch.

India's DGFT issued Notification No. 41/2025-26 on 10 October 2025, inserting a new import policy condition under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy) for Sulfadiazine API (ITC-HS codes 29359013 and 29359090). Imports with a declared CIF value below Rs. 1,774 per kilogram are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 September 2026, aimed at curbing low-priced imports — Global Trade Alert records China, France and Israel among the affected exporters — while protecting domestic API manufacturers.

On 6 October 2025, the US Treasury's Office of Foreign Assets Control (OFAC) designated 8 Mexican individuals and 12 Mexico-based companies under Executive Order 14059 for supplying fentanyl precursor chemicals and laboratory equipment to the Sinaloa Cartel's "Los Chapitos" faction, led by fugitive brothers Archivaldo Ivan and Jesus Alfredo Guzman Salazar (sons of Joaquin "El Chapo" Guzman Loera). The network is centred on Sumilab, a chemical and lab-equipment supplier previously sanctioned by OFAC in May 2023, which restructured through affiliated pharmaceutical, laboratory, chemical, cleaning-supply and real-estate front companies to continue operating after the earlier designation. All property and interests in property of the designated persons within US jurisdiction or held by US persons are blocked, and US persons are generally prohibited from transacting with them.